Cargando…

Comparison of 3-Factor Prothrombin Complex Concentrate and Low-Dose Recombinant Factor VIIa for Warfarin Reversal

INTRODUCTION: Prothrombin complex concentrate (PCC) and recombinant Factor VIIa (rFVIIa) have been used for emergent reversal of warfarin anticoagulation. Few clinical studies have compared these agents in warfarin reversal. We compared warfarin reversal in patients who received either 3 factor PCC...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chapman, Scott A, Irwin, Eric D, Abou-Karam, Nada M, Rupnow, Nichole M, Hutson, Katherine E, Vespa, Jeffrey, Roach, Robert M
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3996494/ https://www.ncbi.nlm.nih.gov/pubmed/24731393 http://dx.doi.org/10.1186/1749-7922-9-27

Ejemplares similares

Prothrombin complex concentrates in warfarin anticoagulation reversal
por: Costa-Lima, Carolina, et al.
Publicado: (2012)

Thromboembolic risks of recombinant factor VIIa use in warfarin-associated intracranial hemorrhage
por: Chou, S, et al.
Publicado: (2011)

Three- versus four-factor prothrombin complex concentrate for the reversal of warfarin-induced bleeding
por: Holt, Tara, et al.
Publicado: (2018)

Four-factor Prothrombin Complex Concentrate for Reversal of Factor Xa Inhibitors versus Warfarin in Life-threatening Bleeding
por: Rech, Megan A., et al.
Publicado: (2021)

Comparison of 3-factor versus 4-factor prothrombin complex concentrate for emergent warfarin reversal: a systematic review and meta-analysis
por: Margraf, David J., et al.
Publicado: (2022)

Thromboembolic risks of recombinant factor VIIa Use in warfarin-associated intracranial hemorrhage: a case–control study
por: H-Y, Chou Sherry, et al.
Publicado: (2012)

Prothrombin Complex Concentrate for Rapid Reversal of Warfarin Anticoagulation to Allow Neuraxial Blockade
por: Skerritt, Conor, et al.
Publicado: (2014)

Evaluation of fixed dose four-factor prothrombin complex concentrate for warfarin reversal at a level 1 trauma center
por: Drone, H, et al.
Publicado: (2015)

Activated prothrombin complex concentrate factor VIII inhibitor bypassing activity (FEIBA) for the reversal of warfarin-induced coagulopathy
por: Wójcik, Cezary, et al.
Publicado: (2009)

Propensity score adjusted comparison of three-factor versus four-factor prothrombin complex concentrate for emergent warfarin reversal: a retrospective cohort study
por: Margraf, David J., et al.
Publicado: (2020)

Preclinical trauma studies of recombinant factor VIIa
por: Schreiber, Martin A, et al.
Publicado: (2005)

Cost effectiveness of recombinant factor VIIa for treatment of intracerebral hemorrhage
por: Kissela, Brett M, et al.
Publicado: (2008)

Use of recombinant factor VIIa in orthotopic liver transplant
por: Bhatia, Pradeep
Publicado: (2011)

Thromboembolic Risk of 4-Factor Prothrombin Complex Concentrate versus Fresh Frozen Plasma for Urgent Warfarin Reversal in the Emergency Department
por: Maguire, Michelle, et al.
Publicado: (2019)

Thromboembolism after treatment with 4-factor prothrombin complex concentrate or plasma for warfarin-related bleeding
por: Go, Alan S., et al.
Publicado: (2022)

Factors contributing to poor outcome in patients on warfarin receiving 4-factor prothrombin complex concentrate in critically ill
por: Mishra, Ajay Kumar, et al.
Publicado: (2021)

Four-factor prothrombin complex concentrate (Beriplex® P/N) is superior to three-factor prothrombin complex concentrate for reversal of coumarin anticoagulation
por: Herzog, E, et al.
Publicado: (2015)

Recombinant factor VIIa in severe trauma: further study needed
por: Galvan, Dan A, et al.
Publicado: (2006)

Recombinant Activated Factor VIIa Treatment for Refractory Hemorrhage in Infants
por: Dang, Chi N, et al.
Publicado: (2010)

Recombinant Factor VIIa: Hemostatic Adjunct in the Coagulopathic Burn Patient
por: Martin, Jeremiah T., et al.
Publicado: (2009)

The utility of recombinant factor VIIa as a last resort in trauma
por: Mamtani, Rishi, et al.
Publicado: (2012)

Recombinant factor VIIa use in patients presenting with intracranial hemorrhage
por: Yampolsky, Natalie, et al.
Publicado: (2014)

Pharmacological characteristics of a novel, recombinant fusion protein linking coagulation factor VIIa with albumin (rVIIa-FP)
por: Zollner, S, et al.
Publicado: (2014)

Use of prothrombin complex concentrate in warfarin anticoagulation reversal in the emergency department: a quality improvement study of administration delays
por: Bordeleau, Simon, et al.
Publicado: (2015)

Recombinant activated factor VIIa and hemostasis in critical care: a focus on trauma
por: Mohr, Alicia M, et al.
Publicado: (2005)

The use of recombinant factor VIIa as a haemostatic agent in ICU patients
por: Vernikos, P, et al.
Publicado: (2004)

Predicting response to recombinant activated factor VIIa administration in the critically ill
por: Pugh, R, et al.
Publicado: (2008)

Diffuse alveolar hemorrhage and recombinant factor VIIa treatment in pediatric patients
por: Park, Jeong A
Publicado: (2016)

Warfarin Reversal With Four-Factor Prothrombin Complex Concentrate for Left Ventricular Assist Device Conversion Surgery Monitored by TEG6s: A Case Report
por: Ito, Hisakatsu, et al.
Publicado: (2022)

A Rare Case of Skin Necrosis Following Extravasation of Prothrombin Complex Concentrate (PCC) Infusion During Warfarin Reversal
por: Smith, Emma C, et al.
Publicado: (2023)

The reversal effect of prothrombin complex concentrate (PCC), activated PCC and recombinant activated factor VII in apixaban‐treated patients in vitro
por: Schultz, Nina H., et al.
Publicado: (2017)

Effect of haemodilution, acidosis, and hypothermia on the activity of recombinant factor VIIa (NovoSeven(®))
por: Viuff, D., et al.
Publicado: (2008)

Evaluation of Recombinant Factor VIIa Treatment for Massive Hemorrhage in Patients with Multiple Traumas
por: Koh, Young Rae, et al.
Publicado: (2012)

Optimal use of recombinant factor VIIa in the control of bleeding episodes in hemophilic patients
por: Puetz, John
Publicado: (2010)

Use of Recombinant Factor VIIa in Symptomatic Intracerebral Hemorrhage Following Intravenous Thrombolysis
por: Yaghi, Shadi, et al.
Publicado: (2015)

Reversal of oral anticoagulation with prothrombin complex concentrate (Octaplex)
por: Riess, H, et al.
Publicado: (2007)

Reversing direct factor Xa or thrombin inhibitors: Factor V addition to prothrombin complex concentrate is beneficial in vitro
por: Brinkman, Herm Jan M., et al.
Publicado: (2022)

The reversal effect of prothrombin complex concentrate (PCC), activated PCC and recombinant activated factor VII against anticoagulation of Xa inhibitor
por: Schultz, Nina Haagenrud, et al.
Publicado: (2017)

Factor VIIa for severe cardiac surgical bleeding
por: Diprose, P, et al.
Publicado: (2002)

Reversibility of Apixaban Anticoagulation with a Four‐Factor Prothrombin Complex Concentrate in Healthy Volunteers
por: Nagalla, S, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_81t1n96tipesn8hfgrhivod128